Garvan Institute will evaluate HealthLinx's prostate cancer biomarkers under one deal, while CPC Clinical Research will liaise with the FDA for HealthLinx's OvPlex test under a separate agreement.
RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.
Consumables sales were up 53 percent during the quarter to an all-time high of $15 million.
The firm has received pre-IDE evaluations from the FDA for BreastGeneDx and is currently looking for partners to help it during the next stage of assay validation.
The Prevail patient registry will be used to analyze primary care ambulatory practices for risk factor management of patients who have a high risk of converting to type 2 diabetes.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.